Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 | O43526 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.43 |
| ▸ | ACP3 | P15309 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.40 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | PTGFR | P43088 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30821928 | 1.00 | KCNQ2 (0.50) | KCNQ2MEN1KMT2ACASP1CXCL8 | |
| SCHEMBL8833604 | 0.89 | KCNQ2 (0.51) | KCNQ2MEN1KMT2ACASP1ACP3 | |
| SCHEMBL20534707 | 0.86 | MEN1 (0.48) | KCNQ2MEN1KMT2ACASP1CXCL8 | |
| SCHEMBL6909558 | 0.86 | MEN1 (0.63) | KCNQ2MEN1KMT2ACXCL8ALDH1A1 | |
| SCHEMBL27935785 | 0.85 | KCNQ2 (0.49) | KCNQ2MEN1KMT2ACASP1ACP3 | |
| SCHEMBL9588027 | 0.85 | KCNQ2 (0.49) | KCNQ2MEN1KMT2ACASP1ACP3 | |
| SCHEMBL2032138 | 0.84 | KCNQ2 (0.48) | KCNQ2MEN1KMT2ACASP1CXCL8 | |
| SCHEMBL23886599 | 0.83 | MEN1 (0.51) | KCNQ2MEN1KMT2ACASP1CXCL8 | |
| SCHEMBL7812432 | 0.83 | MEN1 (0.51) | KCNQ2MEN1KMT2ACASP1CXCL8 | |
| SCHEMBL30370919 | 0.83 | MEN1 (0.51) | KCNQ2MEN1KMT2ACASP1CXCL8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2033635-A1 | Short-chain fatty acid derivatives for treating pruritus | Asan Laboratories Company (Cayman) Limited (CN) | 2009-03-11 | — | — | EP | claimed |
| EP-1951813-A1 | METHOD OF REDUCING THE STYRENE CONTENT OF A POLY (ARYLENE ETHER) POLYSTYRENE BLEND, AND ARTICLES COMPRISING THE RESULTING THERMOPLASTIC RESIN | General Electric Company (US) | 2008-08-06 | — | — | EP | claimed |
| US-20080107646-A1 | Administering phenylbutyric acid derivative and pharmaceutically acceptable carrier | Sunny Pharmtech Inc. (TW) | 2008-05-08 | — | — | US | claimed |
| US-7314909-B2 | Method of reducing the styrene content of a poly(arylene ether)/polystyrene blend, and articles comprising the resulting thermoplastic resin | GENERAL ELECTRIC COMPANY (US) | 2008-01-01 | — | — | US | claimed |
| US-20070264241-A1 | Compounds for Enhanced Cancer Therapy | ZGENE A/S (DK) | 2007-11-15 | — | — | US | claimed |
| WO-2007047217-A1 | METHOD OF REDUCING THE STYRENE CONTENT OF A POLY (ARYLENE ETHER) POLYSTYRENE BLEND, AND ARTICLES COMPRISING THE RESULTING THERMOPLASTIC RESIN | GENERAL ELECTRIC COMPANY (US) | 2007-04-26 | — | — | WO | claimed |
| US-20070083035-A1 | Method of reducing the styrene content of a poly(arylene ether)/polystyrene blend, and articles comprising the resulting thermoplastic resin | SABIC GLOBAL TECHNOLOGIES IP B.V. (NL) | 2007-04-12 | — | — | US | claimed |
| WO-2005079849-A2 | COMPOUNDS FOR ENHANCED CANCER THERAPY | ZGENE A/S (DK) | 2005-09-01 | — | — | WO | claimed |
| US-6403646-B1 | ADMINISTERING PHENYLBUTYRIC ACID OR DERIVATIVES TO TREAT LIVER DISEASE AND EMPHYSEMA CAUSED BY PROTEASE INHIBITOR TYPE Z MUTATION; STIMULATES SECRETION WITHOUT INCREASING SYNTHESIS OF PROTEIN | PERLMUTTER DAVID H (US) | 2002-06-11 | — | — | US | claimed |
| US-5883124-A | ADMINISTERING PHENYLACETIC ACID DERIVATIVE AND RETINOID TO TREAT TUMORS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-03-16 | — | — | US | claimed |
| US-5712307-A | Methods of inducing the production of hemoglobin and treating pathologies associated with abnormal hemoglobin activity using phemylacetic acids and derivatives therof | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-01-27 | — | — | US | claimed |
| US-5710178-A | ARYL- AND ARYLOXYALKANOIC ACIDS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-01-20 | — | — | US | claimed |
| US-5708025-A | BY INDUCING PRODUCTION OF FETAL HEMOGLOBINS BY ADMINISTERING SPECIFIED ARYL ACIDS, DERIVATIVES, SALTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-01-13 | — | — | US | claimed |
| US-5661179-A | ADMINISTERING; TREATS NEUROBLASTOMA, MYELODYSPLASIA, NON-SMALL CELL LUNG CANCER, PROSTATE CANCER, MELANOMA, BRAIN TUMOR, KAPOSI'S SARCOMA, LYMPHOMA, LEUKEMIA, BREAST AND LUNG CANCER, OSTEOSARCOMA AND FIBROSARCOMA | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-08-26 | — | — | US | claimed |
| US-5654333-A | THERAPY FOR ANEMIA, CANCER, AIDS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-08-05 | — | — | US | claimed |
| US-5635533-A | ANTITUMOR AGENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-06-03 | — | — | US | claimed |
| US-5635532-A | ADMINISTERING PHENYL OR NAPHTHYL ACETIC ACID DERIVATIVES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-06-03 | — | — | US | claimed |
| US-5605930-A | ADMINISTERING PHENYLACETIC ACID AS AN INHIBITOR OF THE MEVALONATE PATHWAY | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-02-25 | — | — | US | claimed |
| US-5190946-A | Piperazine compounds restore sensitivity to drug resistant cancer cells | HOFFMANN-LA ROCHE INC. (US) | 1993-03-02 | — | — | US | claimed |
| EP-0443569-A2 | Diamine derivatives and their use in oncology | F. HOFFMANN-LA ROCHE AG (CH) | 1991-08-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070264241-A1 | Compounds for Enhanced Cancer Therapy | TYMP, BAD, NUDT1 | KCNQ2 3243/4885MEN1 2022/4885KMT2A 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.